Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dexmedetomidine 是选择性、具有口服活性的 α2 肾上腺素能受体激动剂,Ki=1.08 nM。它对 α1 肾上腺素受体显示出 1620 倍的选择性。它具有抗焦虑活性,可用于研究促进睡眠和缓解疼痛。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 258 | 现货 | ||
25 mg | ¥ 413 | 现货 | ||
50 mg | ¥ 663 | 现货 | ||
100 mg | ¥ 1,080 | 现货 | ||
200 mg | ¥ 1,580 | 现货 | ||
500 mg | ¥ 2,680 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | Dexmedetomidine is a Central alpha-2 Adrenergic Agonist. The mechanism of action of dexmedetomidine is as an Adrenergic alpha2-Agonist. The physiologic effect of dexmedetomidine is by means of General Anesthesia. |
靶点活性 | α2-adrenoceptor:1.08 nM(Ki ) |
体外活性 | Dexmedetomidine has a relatively high ratio of α2/α1-activity (1620:1 as compared with 220:1 for clonidine) and, therefore, is considered a full agonist of the α2 receptor. This may result in more potent effects of sedation without unwanted cardiovascular effects from α1 receptor activation. The 2-h half-life of dexmedetomidine is nearly 4-fold shorter than that of clonidine, which increases the likelihood that a continuous infusion of dexmedetomidine might be useful for sedation. Dexmedetomidine also has minimum alveolar anesthetic concentration (MAC)-sparing properties, but its use as an anesthetic adjuvant has been complicated by persistent hypotension that has mandated IV fluid administration and vasopressor administration. In addition, its use in large doses is complicated by hypertension from α2 receptor-mediated vascular constriction. |
分子量 | 200.28 |
分子式 | C13H16N2 |
CAS No. | 113775-47-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL (199.72 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.993 mL | 24.965 mL | 49.9301 mL | 124.8252 mL |
5 mM | 0.9986 mL | 4.993 mL | 9.986 mL | 24.965 mL | |
10 mM | 0.4993 mL | 2.4965 mL | 4.993 mL | 12.4825 mL | |
20 mM | 0.2497 mL | 1.2483 mL | 2.4965 mL | 6.2413 mL | |
50 mM | 0.0999 mL | 0.4993 mL | 0.9986 mL | 2.4965 mL | |
100 mM | 0.0499 mL | 0.2497 mL | 0.4993 mL | 1.2483 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dexmedetomidine 113775-47-6 GPCR/G Protein Neuroscience Adrenergic Receptor analgesia Inhibitor (S)-Medetomidine adrenoceptor inhibit (+)-Medetomidine Beta Receptor sedation anxiolysis inhibitor